Latest news with #MichaelMahoney
Yahoo
5 days ago
- Business
- Yahoo
BSX Q2 Deep Dive: Cardiovascular Momentum, New Technologies, and Global Expansion Shape Outlook
Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 22.8% year on year to $5.06 billion. Guidance for next quarter's revenue was optimistic at $4.97 billion at the midpoint, 2.2% above analysts' estimates. Its non-GAAP profit of $0.75 per share was 4.1% above analysts' consensus estimates. Is now the time to buy BSX? Find out in our full research report (it's free). Boston Scientific (BSX) Q2 CY2025 Highlights: Revenue: $5.06 billion vs analyst estimates of $4.89 billion (22.8% year-on-year growth, 3.4% beat) Adjusted EPS: $0.75 vs analyst estimates of $0.73 (4.1% beat) Adjusted EBITDA: $1.51 billion vs analyst estimates of $1.43 billion (29.8% margin, 5.3% beat) Revenue Guidance for Q3 CY2025 is $4.97 billion at the midpoint, above analyst estimates of $4.86 billion Management raised its full-year Adjusted EPS guidance to $2.97 at the midpoint, a 2.2% increase Operating Margin: 16.2%, up from 12.6% in the same quarter last year Organic Revenue rose 17.4% year on year (14.7% in the same quarter last year) Market Capitalization: $159.4 billion StockStory's Take Boston Scientific's second quarter results reflected broad-based strength, with operational sales rising sharply and organic growth notably outpacing the company's underlying market rates. Management attributed the quarter's outperformance to the Cardiovascular segment, particularly the rapid adoption of FARAPULSE for atrial fibrillation and the sustained momentum of the WATCHMAN device. CEO Michael Mahoney highlighted that the 'reliability and trust that the physician community and referring physicians have in [WATCHMAN], along with our clinical and sales team, is driving that.' The company also cited double-digit growth in several international markets and ongoing commercial execution as key contributors to strong top-line and adjusted profitability. Looking ahead, Boston Scientific's updated guidance is grounded in expectations for continued expansion in core cardiovascular therapies, additional product launches, and further international market penetration. Management emphasized that ongoing investments in research and development, as well as anticipated regulatory approvals for devices such as the EMPOWER leadless pacemaker and expanded indications for FARAPULSE, are set to support the company's growth trajectory. CFO Jonathan Monson stated, 'We now expect to expand full year adjusted operating margin by 75 to 100 basis points while increasing our level of investment in R&D to fuel durable, differentiated revenue growth.' Key Insights from Management's Remarks Management pointed to product innovation and market adoption in cardiovascular therapies as the primary drivers of recent performance, while also addressing operational challenges from product discontinuations and tariffs. Cardiovascular growth surge: The Cardiovascular segment led company growth, fueled by strong demand for FARAPULSE (a pulsed field ablation system for atrial fibrillation) and robust performance of the WATCHMAN left atrial appendage closure device. New labeling and expanded indications, particularly in Japan and the U.S., supported broader adoption. WATCHMAN and concomitant procedures: WATCHMAN's uptake was enhanced by the trend toward concomitant procedures, where atrial fibrillation ablation and appendage closure are performed together. Over 60% of U.S. electrophysiologists using WATCHMAN are adopting this approach, following recent clinical data and reimbursement changes. Management expects ongoing growth as clinical evidence and payer support evolve. Impact of product discontinuation: The global discontinuation of the ACURATE valve led to inventory write-downs and pressured gross margins. However, management highlighted that strong revenue growth and 'spend control' offset these headwinds, keeping full-year margin guidance intact. Geographic diversification: The Asia Pacific region posted double-digit growth, led by Japan and China, where new product launches and expanded clinical indications contributed. The company expects mid-teens growth in China to continue, citing the diversification of its portfolio and ongoing investment in commercial capabilities. Strategic acquisitions: Recent acquisitions of SoniVie (ultrasound-based therapy for hypertension) and Intera Oncology (liver cancer therapies) are intended to strengthen the company's portfolio in targeted adjacencies. Management noted that these additions align with Boston Scientific's strategy to address large, growing end markets and complement existing franchises. Drivers of Future Performance Boston Scientific's forward outlook is anchored by continued innovation, expanded product approvals, and a focus on international growth, balanced against expected tariff and reimbursement headwinds. Expanded product indications: Management anticipates growth from regulatory approvals for new devices and expanded indications, including the expected launch of the EMPOWER leadless pacemaker and additional labeling for FARAPULSE in Japan and China. These approvals are seen as key to increasing the company's addressable market and supporting durable revenue growth. Ongoing R&D and investment: The company plans to maintain elevated investment in research and development, particularly to accelerate clinical trials and support upcoming product launches. This includes expanding clinical evidence for products such as FARAPULSE and WATCHMAN, which management believes will reinforce competitive positioning. External pressures and risk management: Tariffs and reimbursement changes—such as proposed cuts to Medicare payments for certain cardiac procedures—present headwinds. Management stated that they expect a $100 million tariff headwind for the year but intend to offset these impacts through sales mix improvements and expense discipline. They also acknowledged the need for ongoing engagement with medical societies to address reimbursement challenges. Catalysts in Upcoming Quarters Looking ahead, the StockStory team will focus on (1) the pace and commercial impact of new product launches and regulatory approvals, (2) the sustainability of double-digit growth in key international markets such as China and Japan, and (3) the company's ability to manage margin pressures from tariffs and reimbursement changes. Progress in integrating recent acquisitions and execution on clinical trial milestones will also be important indicators. Boston Scientific currently trades at $108.70, up from $103.22 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). Our Favorite Stocks Right Now When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-06-2025
- Business
- Yahoo
Boston Scientific's Q1 Earnings Call: Our Top 5 Analyst Questions
Boston Scientific's first quarter results were met with a positive market reaction following revenue and profit that surpassed Wall Street expectations. Management credited robust growth in its cardiology portfolio and the successful execution of a category leadership strategy spanning electrophysiology, WATCHMAN, and interventional cardiology products. CEO Michael Mahoney highlighted that double-digit expansion in the U.S. and momentum in Europe and Japan helped drive operational sales growth, while new product launches and increased adoption in emerging segments, such as FARAPULSE and Axios, also contributed to performance. Is now the time to buy BSX? Find out in our full research report (it's free). Revenue: $4.66 billion vs analyst estimates of $4.57 billion (20.9% year-on-year growth, 2% beat) Adjusted EPS: $0.75 vs analyst estimates of $0.67 (11.5% beat) Revenue Guidance for Q2 CY2025 is $4.88 billion at the midpoint, above analyst estimates of $4.79 billion Management raised its full-year Adjusted EPS guidance to $2.91 at the midpoint, a 2.5% increase Operating Margin: 19.8%, up from 17.5% in the same quarter last year Organic Revenue rose 18.2% year on year (13.1% in the same quarter last year) Market Capitalization: $150.5 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Robert Marcus (JPMorgan) asked about mitigating tariff headwinds. CFO Daniel Brennan explained the offset through increased revenue and targeted cost reductions, with no plans for major manufacturing shifts. Larry Biegelsen (Wells Fargo) questioned global electrophysiology market share. CEO Michael Mahoney acknowledged strong momentum and the goal of reaching #1, particularly through investments in China and Japan. Joanne Wuensch (Citi) inquired about WATCHMAN's growth and procedural trends. Mahoney and Dr. Ken Stein cited rapid adoption of concomitant procedures and favorable clinical data as key drivers. Travis Steed (Bank of America) asked about margin sustainability. Brennan attributed margin expansion to product mix and noted that tariffs will pressure gross margin in the second half, but full-year expansion is still expected. Danielle Antalffy (UBS) raised questions on the SoniVie acquisition's timing and potential. Mahoney described the clinical trial process and anticipated a multi-year path to realizing commercial contributions. In upcoming quarters, the StockStory team will monitor (1) continued growth and market share gains in electrophysiology and WATCHMAN, (2) progress on integrating new acquisitions and the resulting product launches, and (3) the company's ability to offset tariff-related cost pressures without sacrificing margin targets. Updates on key clinical trials and regulatory milestones will also be critical to tracking Boston Scientific's strategy execution. Boston Scientific currently trades at $101.38, up from $94.97 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
Yahoo
10-06-2025
- Business
- Yahoo
Co-operators moves to Guidewire cloud for claims management
Canadian multi-line insurer Co-operators has migrated its Guidewire ClaimCenter to the Guidewire Cloud Platform, aiming to enhance the company's claims management capabilities. The transition encompasses most of Co-operators' property and casualty (P&C) lines of business across the provinces it operates in. It also includes the transition of its subsidiary, Sovereign Insurance, into the same cloud-based system. This follows the migration of Co-operators' Guidewire PolicyCenter and Guidewire BillingCenter to the Guidewire Cloud Platform earlier in 2023. Co-operators chief information officer and executive vice-president Harry Pickett said: 'This was a multi-year transformation for Co-operators, a successful result of collaboration across our P&C Business and Technology teams and Guidewire. We leveraged our learnings from our previous PolicyCenter and BillingCenter migration to accomplish this modernisation on time and with little disruption to our claims process. 'The full suite on the Guidewire Cloud Platform provides us with more stability and security, and establishes a solid foundation for future enhancements, enabling us to be faster in implementing new features and capabilities that will deliver value to our stakeholders.' The organisation has been a client of Guidewire since 2007. Guidewire professional services head Michael Mahoney stated: 'We congratulate Co-operators on its successful ClaimCenter implementation project on Guidewire Cloud Platform and concluding its full InsuranceSuite migration. We look forward to working with the company to grow its business and continue providing financial security for Canadians and their communities, as it has done for the past 80 years.' Last month, Argentine insurer San Cristóbal Seguros deployed Guidewire InsuranceSuite on Guidewire Cloud. "Co-operators moves to Guidewire cloud for claims management " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
09-06-2025
- Business
- Yahoo
Co-operators Transforms Claims Operations with Guidewire ClaimCenter on Guidewire Cloud Platform
Subsidiary Sovereign Insurance also leveraging ClaimCenter for claims management GUELPH, Ontario & SAN MATEO, Calif., June 09, 2025--(BUSINESS WIRE)--Co-operators, a leading Canadian multi-line insurance and financial services organization, and Guidewire (NYSE: GWRE) announced that Co-operators successfully implemented Guidewire ClaimCenter on Guidewire Cloud Platform to power its claims management functions, adapt to changing market demands, and deliver more value to policyholders. A Guidewire customer since 2007, Co-operators migrated ClaimCenter to Guidewire Cloud Platform simultaneously for most of its property and casualty (P&C) lines of business in the provinces where it operates. The company also extended its ClaimCenter instance on Guidewire Cloud Platform to its subsidiary Sovereign Insurance. Co-operators previously migrated Guidewire PolicyCenter and Guidewire BillingCenter to Guidewire Cloud Platform in 2023. With the conclusion of this project, the majority of the company's P&C Operations are now a full Guidewire InsuranceSuite customer on Guidewire Cloud Platform. "This was a multi-year transformation for Co-operators, a successful result of collaboration across our P&C Business and Technology teams and Guidewire," said Harry Pickett, Executive Vice President and Chief Information Officer at Co-operators. "We leveraged our learnings from our previous PolicyCenter and BillingCenter migration to accomplish this modernization on time and with little disruption to our claims process. The full suite on the Guidewire Cloud Platform provides us with more stability and security, and establishes a solid foundation for future enhancements, enabling us to be faster in implementing new features and capabilities that will deliver value to our stakeholders." "We congratulate Co-operators on its successful ClaimCenter implementation project on Guidewire Cloud Platform and concluding its full InsuranceSuite migration," commented Guidewire Head of Professional Services Michael Mahoney. "We look forward to working with the company to grow its business and continue providing financial security for Canadians and their communities as it's done for the past 80 years." About Co-operators: Proudly Canadian since 1945, Co‑operators is a leading financial services co-operative, offering multi-line insurance and investment products, services, and personalized advice to help Canadians build their financial strength and security. With more than $72 billion in assets under administration, Co‑operators is well known for its community involvement and its commitment to sustainability. Currently a carbon neutral organization, Co-operators is committed to net-zero emissions in its operations and investments by 2040, and 2050, respectively. Co‑operators is recognized as one of Canada's Top 100 Employers and ranked as one of Corporate Knights' Best 50 Corporate Citizens in Canada. For more information, please visit About Guidewire Software Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurance brands in 42 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence, Guidewire defines cloud platform excellence for P&C insurers. We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and SI partner ecosystem. Our marketplace represents the largest solution partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation. For more information, please visit and follow us on X (formerly known as Twitter) and LinkedIn. NOTE: For information about Guidewire's trademarks, visit View source version on Contacts Albert LinPublic Relations ManagerGuidewire Software, Inc.+1-415-205-4214allin@ Co-operators Media Relationsmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
09-06-2025
- Business
- Business Wire
Co-operators Transforms Claims Operations with Guidewire ClaimCenter on Guidewire Cloud Platform
GUELPH, Ontario & SAN MATEO, Calif.--(BUSINESS WIRE)-- Co-operators, a leading Canadian multi-line insurance and financial services organization, and Guidewire (NYSE: GWRE) announced that Co-operators successfully implemented Guidewire ClaimCenter on Guidewire Cloud Platform to power its claims management functions, adapt to changing market demands, and deliver more value to policyholders. A Guidewire customer since 2007, Co-operators migrated ClaimCenter to Guidewire Cloud Platform simultaneously for most of its property and casualty (P&C) lines of business in the provinces where it operates. The company also extended its ClaimCenter instance on Guidewire Cloud Platform to its subsidiary Sovereign Insurance. Co-operators previously migrated Guidewire PolicyCenter and Guidewire BillingCenter to Guidewire Cloud Platform in 2023. With the conclusion of this project, the majority of the company's P&C Operations are now a full Guidewire InsuranceSuite customer on Guidewire Cloud Platform. 'This was a multi-year transformation for Co-operators, a successful result of collaboration across our P&C Business and Technology teams and Guidewire,' said Harry Pickett, Executive Vice President and Chief Information Officer at Co-operators. 'We leveraged our learnings from our previous PolicyCenter and BillingCenter migration to accomplish this modernization on time and with little disruption to our claims process. The full suite on the Guidewire Cloud Platform provides us with more stability and security, and establishes a solid foundation for future enhancements, enabling us to be faster in implementing new features and capabilities that will deliver value to our stakeholders.' 'We congratulate Co-operators on its successful ClaimCenter implementation project on Guidewire Cloud Platform and concluding its full InsuranceSuite migration,' commented Guidewire Head of Professional Services Michael Mahoney. 'We look forward to working with the company to grow its business and continue providing financial security for Canadians and their communities as it's done for the past 80 years.' About Co-operators: Proudly Canadian since 1945, Co‑operators is a leading financial services co-operative, offering multi-line insurance and investment products, services, and personalized advice to help Canadians build their financial strength and security. With more than $72 billion in assets under administration, Co‑operators is well known for its community involvement and its commitment to sustainability. Currently a carbon neutral organization, Co-operators is committed to net-zero emissions in its operations and investments by 2040, and 2050, respectively. Co‑operators is recognized as one of Canada's Top 100 Employers and ranked as one of Corporate Knights' Best 50 Corporate Citizens in Canada. For more information, please visit About Guidewire Software Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurance brands in 42 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence, Guidewire defines cloud platform excellence for P&C insurers. We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and SI partner ecosystem. Our marketplace represents the largest solution partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation. For more information, please visit and follow us on X (formerly known as Twitter) and LinkedIn. NOTE: For information about Guidewire's trademarks, visit .
